MARKET

CGEN

CGEN

Compugen
NASDAQ
0.6550
-0.0140
-2.09%
Opening 09:36 11/30 EST
OPEN
0.6600
PREV CLOSE
0.6690
HIGH
0.6600
LOW
0.6527
VOLUME
17.47K
TURNOVER
0
52 WEEK HIGH
1.490
52 WEEK LOW
0.5300
MARKET CAP
57.85M
P/E (TTM)
-1.8119
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at CGEN last week (1120-1124)?
Weekly Report · 3d ago
Weekly Report: what happened at CGEN last week (1113-1117)?
Weekly Report · 11/20 09:43
Weekly Report: what happened at CGEN last week (1106-1110)?
Weekly Report · 11/13 09:40
Compugen: Report of foreign issuer
Press release · 11/07 13:12
Compugen GAAP EPS of -$0.11 misses by $0.02
Seeking Alpha · 11/07 12:06
Compugen Q3 EPS $(0.11) Misses $(0.09) Estimate. Cash And Equivalents $57.5M
Benzinga · 11/07 12:05
Compugen Q3 2023 Earnings Preview
Compugen ltd. is scheduled to announce its q3 earnings on november 7th. the consensus eps estimate is -$0.12 and the consensus revenue estimate is $2.5m. compugen's q3 2023 results will be released before market open.
Seeking Alpha · 11/06 18:12
Notable earnings before Tuesday's open
Major earnings expected before the bell on tuesday include: air products and chemicals, d.r. horton, emerson electric and uber technologies. other notable companies to report before tuesday's open include: at&t, ge, at&e, ge capital, ge energy, and ge capital partners.
Seeking Alpha · 11/06 15:30
More
About CGEN
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.

Webull offers Compugen Ltd. (USA) stock information, including NASDAQ: CGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CGEN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CGEN stock methods without spending real money on the virtual paper trading platform.